MEDIZINISCHE UNIVERSITAT INNSBRUCK

Their core work

Medical University of Innsbruck is a specialized medical research university in Austria focused on translational biomedical research — turning laboratory discoveries into clinical applications. Their core strengths lie in cancer immunology, neuroscience (particularly within the Human Brain Project), neurodegenerative disease research, and diabetes technology including artificial pancreas systems. They contribute deep expertise in immunotherapy, computational neuroscience, and clinical trial design to large European research consortia, while also leading their own ERC-funded programs in cancer immunity and cell biology.

What they specialise in

How they've shifted over time

In the early H2020 period (2015–2018), MUI concentrated heavily on brain simulation within the Human Brain Project, diabetes management technologies, and foundational cancer biology — keywords like 'mouse brain', 'simulation', 'neuroinformatics', and 'insulin pump therapy' dominated. From 2019 onward, the focus shifted noticeably toward neurodegeneration, neuroinflammation, cancer immunology (with three coordinated ERC grants), and research infrastructure including atmospheric monitoring. The university has clearly matured from a computational neuroscience contributor into a leader in immuno-oncology while maintaining its neuroscience roots.

MUI is consolidating leadership in cancer immunity and immune checkpoint research, making them an increasingly strong partner for immuno-oncology and precision medicine consortia.

How they like to work

MUI operates primarily as an active research partner (32 of 39 projects), but has demonstrated strong leadership capability through 6 coordinated projects — notably three ERC Advanced Grants in cancer biology (EPIC, HOPE, POLICE). With 630 unique consortium partners across 47 countries, they are a well-connected hub rather than a niche contributor, comfortable in both large multi-partner consortia (HBP, EU-ToxRisk) and focused research teams. Their breadth of partnerships suggests they are easy to integrate into new consortia and bring established credibility.

MUI has collaborated with 630 unique partners across 47 countries, making them one of the most broadly networked medical universities in the H2020 landscape. Their partnerships span from large pan-European clinical trials to specialized computational infrastructure projects, with no single geographic dependency.

What sets them apart

MUI combines deep clinical medicine expertise with serious computational and bioinformatics capability — a rare pairing for a medical university. Their triple ERC Advanced Grant portfolio in cancer immunity (EPIC, HOPE, POLICE) signals world-class principal investigators in immuno-oncology. For consortium builders, MUI offers both the wet-lab disease biology and the data science muscle to bridge experimental and computational workpackages.

Highlights from their portfolio

• HOPE
  Largest single grant (EUR 2.48M) — an ERC Advanced Grant targeting the intracellular immune checkpoint NR2F6 in lung cancer, signaling frontier research in immuno-oncology.
• HBP SGA1
  Part of the flagship Human Brain Project (EUR 1.52M contribution), placing MUI at the center of Europe's largest neuroscience initiative.
• EPIC
  Coordinator of a EUR 2.46M ERC grant on precision immunotherapy for colorectal cancer, demonstrating leadership in translational cancer research.